Factor Bioscience engineers cells to develop advanced therapies, focusing on mRNA, gene editing, cell reprogramming, and nucleic acid delivery to create allogeneic cell therapies. The company emphasizes collaboration with strategic partners to accelerate development of transformational medicines and has a strong emphasis on regenerative and immuno-oncology applications, with operations based in Cambridge, Massachusetts and other sites. Their work centers on rewriting cellular programs to repair mutations, resist infections, and enhance cancer immunotherapies, supported by a patent portfolio and in-house manufacturing capabilities.
No recent news for this company.